State Street Corp Raises Position in Curis, Inc. (CRIS)

State Street Corp grew its position in Curis, Inc. (NASDAQ:CRIS) by 10.4% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,857,044 shares of the biotechnology company’s stock after purchasing an additional 175,424 shares during the quarter. State Street Corp owned about 1.29% of Curis worth $3,511,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Royal Bank of Canada grew its holdings in Curis by 4.9% in the second quarter. Royal Bank of Canada now owns 956,717 shares of the biotechnology company’s stock worth $1,808,000 after purchasing an additional 44,421 shares during the last quarter. Goldman Sachs Group Inc. grew its holdings in Curis by 1.6% in the second quarter. Goldman Sachs Group Inc. now owns 119,638 shares of the biotechnology company’s stock worth $226,000 after purchasing an additional 1,880 shares during the last quarter. Voya Investment Management LLC grew its holdings in Curis by 21.8% in the second quarter. Voya Investment Management LLC now owns 68,138 shares of the biotechnology company’s stock worth $129,000 after purchasing an additional 12,207 shares during the last quarter. OxFORD Asset Management LLP acquired a new stake in shares of Curis during the second quarter worth $115,000. Finally, Vanguard Group Inc. lifted its stake in shares of Curis by 2.6% during the second quarter. Vanguard Group Inc. now owns 4,955,068 shares of the biotechnology company’s stock worth $9,365,000 after buying an additional 127,443 shares during the period. 55.22% of the stock is currently owned by institutional investors and hedge funds.

In related news, CEO Ali Ph.D. Fattaey bought 50,000 shares of the business’s stock in a transaction dated Wednesday, November 15th. The stock was acquired at an average price of $1.06 per share, with a total value of $53,000.00. Following the completion of the purchase, the chief executive officer now directly owns 115,890 shares of the company’s stock, valued at $122,843.40. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. 4.07% of the stock is owned by insiders.

Several research firms have recently commented on CRIS. Zacks Investment Research downgraded shares of Curis from a “hold” rating to a “sell” rating in a research note on Tuesday, October 3rd. ValuEngine downgraded shares of Curis from a “hold” rating to a “sell” rating in a research note on Friday, September 15th. BidaskClub upgraded shares of Curis from a “strong sell” rating to a “sell” rating in a research note on Thursday, August 17th. Finally, Guggenheim initiated coverage on shares of Curis in a research report on Monday, October 23rd. They set a “buy” rating and a $7.00 target price for the company. Three equities research analysts have rated the stock with a sell rating and three have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $6.50.

Curis, Inc. (CRIS) opened at $0.84 on Friday. Curis, Inc. has a 1 year low of $0.79 and a 1 year high of $3.48. The company has a debt-to-equity ratio of 1.24, a quick ratio of 5.15 and a current ratio of 5.15.

Curis (NASDAQ:CRIS) last issued its quarterly earnings data on Tuesday, November 7th. The biotechnology company reported ($0.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.02). The firm had revenue of $2.44 million during the quarter, compared to analyst estimates of $2.19 million. Curis had a negative return on equity of 250.58% and a negative net margin of 629.29%. The company’s revenue was up 38.6% on a year-over-year basis. During the same quarter last year, the company posted ($0.21) EPS. analysts forecast that Curis, Inc. will post -0.41 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “State Street Corp Raises Position in Curis, Inc. (CRIS)” was first reported by Week Herald and is the sole property of of Week Herald. If you are viewing this report on another site, it was illegally copied and reposted in violation of United States and international copyright and trademark law. The legal version of this report can be read at https://weekherald.com/2017/12/10/state-street-corp-raises-position-in-curis-inc-cris.html.

About Curis

Curis, Inc is a biotechnology company seeking to develop and commercialize drug candidates for the treatment of cancers. The Company’s drug candidate is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. CUDC-907 is an oral, dual inhibitor of Class I and II HDAC, as well as Class I PI3K enzymes.

Want to see what other hedge funds are holding CRIS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Curis, Inc. (NASDAQ:CRIS).

Institutional Ownership by Quarter for Curis (NASDAQ:CRIS)

Receive News & Ratings for Curis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply